Itraconazole significantly inhibited breast cancer resistance protein, BCRP, efflux pump, thereby lowering cytotoxicity resistance to topotecan [203] and leukemia cell line resistance to doxorubicin and etoposide [204]. This evidence concerns the gene ABCG2 and leukemia.